NPPA and myeloid sarcoma: The first clinical observation that related the possible participation of the kynurenine pathway (KP) in MS was that reduced levels of tryptophan were observed both in blood and in cerebrospinal fluid (CSF), which implied that there was greater activation of KP in the CNS of these patients [7].